

## **Bachem and ILS extend their collaboration in Japan by an Exclusive Agency Agreement**

Bubendorf/Basel, Switzerland and Ibaraki, Japan, September 7th, 2015 – Bachem (SIX: BANB) and ILS announce today that they will strengthen their co-marketing efforts in Japan. The two companies have been establishing a close collaboration for more than a decade, already. Based on a Sales and Marketing agreement which was signed in 2012, ILS is providing Bachem manufactured Active Pharmaceutical Ingredients (APIs) to Japanese customers. In the course of the acquisition of American Peptide Company, Inc. (APC), based in California USA, and its transfer from ILS to Bachem, both companies underlined their intentions to extend the current business relations. Under the agreement reached, ILS will be the Exclusive Agent for Japan for all peptide-based products of the Bachem Group; this applies to non-GMP research chemicals as well as for cGMP grade APIs. In addition, ILS will register Drug Master Files in Japan for APIs manufactured by Bachem.

Dr. José de Chastonay, Chief Marketing Officer of Bachem Holding AG, comments:

*“We are pleased to extend our successful long term collaboration with ILS. Indeed, we recognize their acumen to market successfully peptidic APIs in Japan. Our relationship spans more than a decade in which we have worked harmoniously and successfully together. To enter into an exclusive agreement will consolidate our position in the highly demanding Japanese Market.”*

Mr. Takahiro Ogata, President of ILS Inc., continues:

*“We have been selling Bachem manufactured APIs for years, although the majority of our peptide business were APC’s products. Now, as APC is a part of the Bachem Group, we are really enthusiastic about extending our partnership with Bachem. They are a highly reliable source of both research grade peptides from catalog or custom synthesis and cGMP manufactured APIs from small to very large scale. Based on this agreement, ILS provides its customers the largest possible selection of research grade peptides, the reliable supply of peptidic APIs and the highly qualified technical support from Bachem’s experts.”*

### **About Bachem**

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and knowhow than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

### **Bachem. Pioneering Partner for Peptides**

### **About ILS**

ILS, Initiative for Life Sciences, has been engaged in the business of pharmaceuticals and functional foods for more than 20 years in Japan. ILS holds marketing approval for peptidic pharmaceuticals and has broad experience in research, development and formulation of peptides.

### **Contact:**

For further questions, please visit our websites or contact the person below.

**Bachem Holding AG**  
**Stephan Schindler, CFO**  
Tel.: +41 61 935 2333  
Fax: +41 61 935 2324  
[ir@bachem.com](mailto:ir@bachem.com)  
[www.bachem.com](http://www.bachem.com)

**ILS Inc.**  
**Takahiro Mizumoto,**  
**Operating Officer,**  
**Senior Manager of Sales dept.**  
Tel.: +81 297 45 6342  
Fax. +81 297 45 6353  
[info@ils.co.jp](mailto:info@ils.co.jp)  
[www.ils.co.jp](http://www.ils.co.jp)